天圣制药集团股份有限公司 2025年度业绩预告

Group 1 - The company expects a net loss for the fiscal year 2025, with the performance forecast period from January 1, 2025, to December 31, 2025 [1] - The financial data related to the performance forecast has not been audited by the accounting firm, but preliminary communication indicates no significant discrepancies [1][2] Group 2 - The primary reason for the expected loss is high fixed costs, particularly depreciation expenses on fixed assets [2] - The company anticipates a reduction in losses compared to the previous year, mainly due to a decrease in the provision for impairment of fixed assets [2]